AI assistant
Edwards Lifesciences Corp — Director's Dealing 2021
Sep 9, 2021
30042_dirs_2021-09-08_6709e2b1-ac37-4d1a-bcc0-13cfb825a5e4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-09-08
Reporting Person: Szyman Catherine M. (CVP, Critical Care)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-08 | Common Stock | M | 9741.0000 | $21.7600 | Acquired | 37155.5223 | Direct |
| 2021-09-08 | Common Stock | S | 9741.0000 | $121.2773 | Disposed | 27414.5223 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-08 | Employee Stock Option (Right to Acquire) | $21.7600 | M | 9741.0000 | Disposed | 2022-05-13 | Common Stock (9741.0000) | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021.
F2: This transaction was executed in multiple trades at prices ranging from $120.9950 to $121.7000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.